Courage Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Courage Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4,000	Closed	-$291K	–	30
2022 Q1	$291K	Hold	4,000	–	–	0.28%	30
2021 Q4	$473K	Hold	4,000	–	–	0.31%	31
2021 Q3	$537K	Hold	4,000	–	–	0.29%	33
2021 Q2	$648K	Sell	4,000 -2,000	-33%	-$156K	0.39%	30
2021 Q1	$482K	Hold	6,000	–	–	0.35%	32
2020 Q4	$326K	Buy	+6,000	New	+$218K	0.32%	30
2018 Q4	–	Sell	-7,000	Closed	-$200K	–	21
2018 Q3	$200K	Sell	7,000 -8,800	-56%	-$256K	0.11%	24
2018 Q2	$432K	Buy	+15,800	New	+$383K	0.32%	18
2018 Q1	–	Sell	-7,200	Closed	-$138K	–	30
2017 Q4	$138K	Buy	+7,200	New	+$166K	0.1%	24

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Courage Capital Management's NTLA Position: Q2 2022 in Review

Courage Capital Management sold out of Intellia Therapeutics (NTLA) in Q2 2022, closing a stake of 4,000 shares — an estimated $291K sold.

Courage Capital Management first reported a position in NTLA in Q4 2017 and held it in 9 quarters. The position peaked at $648K in Q2 2021. 299 funds tracked by Wall St. Rank hold NTLA as of Q2 2022.

Courage Capital Management reported no remaining Intellia Therapeutics position as of Q2 2022 after selling out during the quarter.
Courage Capital Management sold 4,000 Intellia Therapeutics shares in Q2 2022, an estimated $291K.
Courage Capital Management first reported a position in Intellia Therapeutics in Q4 2017 and held it in 9 quarters.
Courage Capital Management's Intellia Therapeutics position peaked at $648K in Q2 2021.
299 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2022.

Based on Courage Capital Management's 13F filing for Q2 2022, filed 12 Aug 2022.